USPTO serial 99933476
VIEWPOINT BIOPHARMA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- —
- Law office
- —
What this means
Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.
Need help with VIEWPOINT BIOPHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sandra L Etherton
Sandra L Etherton ETHERTON LAW GROUP, LLCPO Box 13808Scottsdale, AZ 85267United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Radiopharmaceutical chemical compounds; radiolabeled chemical compounds comprising alpha-emitting radionuclides; bifunctional chelating agents for conjugating radionuclides to targeting molecules; chemical precursors for use in the manufacture of radiopharmaceuticals; chelating compounds for radiolabeling of peptides and small molecules; radioactive isotope-labeled chemical intermediates for pharmaceutical research and manufacturing | ACTIVE | — |
| 005 | Radiopharmaceutical preparations; Radiopharmaceutical preparations for the treatment of cancer; radiopharmaceutical preparations for the diagnosis of cancer; targeted alpha therapy radiopharmaceutical preparations for the treatment of cancer; radioligand therapy preparations comprising radiolabeled targeting compounds for oncological use; radiopharmaceutical diagnostic agents for use in nuclear medicine imaging; radiopharmaceutical preparations for the treatment of cancers; radiolabeled peptide conjugates for use in cancer therapy; radiopharmaceutical preparations for theranostic applications in oncology | ACTIVE | — |
| 042 | nuclear medicine; contract research services in the field of radiopharmaceutical drug discovery and development; preclinical research and development services relating to radiolabeled compounds for cancer therapy and diagnosis; scientific consultation services in the field of targeted radionuclide therapy; laboratory research services in the field of radiochemistry and radiopharmaceutical development; drug discovery research services in the field of oncology radiopharmaceuticals; scientific and technological services relating to the development of radiolabeled targeted alpha therapy compounds; research and development services relating to theranostic radiopharmaceutical platforms | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 10, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 10, 2026 | NWAP | NEW APPLICATION ENTERED | — |